TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Everest Medicines Ltd. ( (HK:1952) ).
Everest Medicines Ltd. announced significant changes in its board of directors, effective October 10, 2025. Mr. Wei Fu has been re-designated as a non-executive director and appointed as honorary chairman, stepping down from his roles as chairman of the board and committees to focus on other business endeavors. Mr. Yifang Wu has been appointed as the new executive director and chairman, indicating a strategic leadership transition aimed at guiding the company’s future growth and operations.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on the development and commercialization of transformative pharmaceutical products. The company primarily targets the Asian market, aiming to address critical unmet medical needs.
Average Trading Volume: 6,016,978
Technical Sentiment Signal: Buy
Current Market Cap: HK$19.87B
Find detailed analytics on 1952 stock on TipRanks’ Stock Analysis page.